Inventiva announces the closing of $107.7 million initial public offering on the Nasdaq Global Market

Daix (France), July 15, 2020 – INVENTIVA S.A. (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need, announced today the closing of its previously announced initial public offering on the Nasdaq Global Market of an aggregate of 7,478,261 new ordinary shares in the form of American Depositary Shares (“ADSs”), each representing one ordinary share, at an offering price of $14.40 per ADS (the “Offering”). Aggregate gross proceeds of the Offering, before deducting underwriting commissions and estimated expenses payable by the Company, were approximately $107.7 million (€94.9 million¹). All of the securities in the Offering were offered by Inventiva.

Inventiva’s ordinary shares are listed on Euronext Paris under the symbol “IVA” and its ADSs are listed on the Nasdaq Global Market under the symbol “IVA”. The ADSs began trading on the Nasdaq Global Market on July 10, 2020.

Jefferies LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC acted as Joint Global Coordinators and bookrunners for the Offering. H.C. Wainwright & Co., LLC acted as lead manager and Roth Capital Partners, LLC and KBC Securities USA LLC acted as co-managers for the Offering (together, the “Underwriters”).

Namsen Capital is acting as Inventiva’s capital markets advisor.

A registration statement relating to these securities, including a prospectus, was declared effective by the U.S. Securities and Exchange Commission (“SEC”) on July 9, 2020. The Offering was made only by means of a prospectus. Copies of the final prospectus relating to and describing the terms of the Offering can be obtained from Jefferies LLC, 520 Madison Avenue New York, NY 10022, or by telephone at 877-547-6340 or 877-821-7388, or by email at [e-mail]; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104 or by telephone at [phone] or by email at [e-mail]; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at 212-518-9544, or by email at [e-mail]. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.